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Grâce à un dépistage de deux séries d’agents de contrastes, DOTA (acide 1,4,7,10-tétraazacyclododé-
cane-1,4,7,10-tétraacétique) et DTPA (acide diéthylènetriaminepentaacétique), ce projet vise à trouver 
la meilleure méthode afin de mesurer la thrombine dans le sérum. L’utilisation de cette technologie avec 
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Thrombin is an enzyme that converts soluble fibrinogen into 
insoluble strands of fibrin (which works with platelets to form 
a blood clot). MR imaging of thrombin could be useful in the 
imaging of blood clots (thrombus and embolus).  An MRI con-
trast agent can be made more specific for a certain protein by 
conjugating (joining) it to an aptamer. An aptamer is a synthe-
sized single-stranded DNA, targeted (through a process called 
SELEX) to a specific protein. The development of a targeted 
MRI contrast agent could enhance the diagnostic value of the 
obtained MR images. Through screening two series of contrast 
agents, DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tet-
raacetic acid) and DTPA (diethylenetriaminepentaacetic acid), 
this project hopes to find the best system for measuring thrombin 
in serum. This use of aptamer technology (and DNA synthesis) 
appears to be a unique method of targeting thrombin rather than 
the more invasive angiography and angioscopy procedures. 
The first phase of this project involved the synthesis of aptam-
er-DOTA and aptamer-DTPA conjugates. Progress towards the 
development of these conjugates is presented. Upon success-
ful synthesis of the aptamer conjugates, they could be screened 
to find the best system for measuring thrombin in serum.
La thrombine est une enzyme qui convertit le fibrinogène solu-
ble en brins de fibrine insoluble (ce qui permet aux plaquettes 
de former un caillot de sang). L’imagerie à résonance magné-
tique (IRM) de la thrombine pourrait être utile pour l’imagerie de 
caillots sanguins (thrombus et embolie). Un agent de contraste 
IRM peut être conçu pour viser plus spécifiquement une certaine 
protéine par voie de conjugaison (liaison) à un aptamère. Un ap-
tamère est simple brin d’ADN synthétisé, qui cible (par le proces-
sus SELEX) une protéine spécifique. L’élaboration d’un agent 
de contraste IRM ciblée envers une protéine particulière pour-
rait améliorer la valeur diagnostique des images IRM obtenues. 
Aptamer technology is an emerg-
ing tool that utilizes engineered 
strands of DNA or RNA oligo-
mers to bind a target with high 
affinity. Because of its low tox-
icity, aptamers can have many 
applications in biotechnology 
and clinical research. Conven-
tional magnetic resonance imag-
ing (MRI) contrast agents (CA) 
are administered as ions bound 
to a chelator. This conventional 
imaging method lacks specificity 
to areas of interest, compromis-
ing precision. Here, Daphnee 
Dubouchet-Olsheski aims to 
build specificity into an MRI CA 
used to image blood clots. For 
this, a thrombin-specific aptam-
er is conjugated to a CA chela-
tor, tethering the contrast agent 
to thrombin. Daphnee explores 
the initial steps required to syn-
thesize chelator-aptamer candi-
dates that will be used in future 
studies. Aptamers integrated into 
medical technology can provide 
an innovative solution to sharpen 
the contrast of conventional MRI.
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aptamère (et avec la synthèse de l’ADN) semble être une méthode unique afin de cibler la trombine de 
manière moins invasive que les procédures d’angiographie ou d’angioscopie. La première phase de ce 
projet consistait de la synthèse du conjugué de l’aptamère DOTA et de l’aptamère DTPA. Le progrès vers 
l’élaboration de ces conjugués est présenté dans cet article. Dès la réussite de la synthèse des conjugués 
d’aptamères, ces derniers pourraient être en mesure d’être évalué afin de trouver la meilleure méthode 
pour mesurer la thrombine dans le sérum.
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Background
Magnetic resonance imaging (MRI) is a common 
medical technique used to obtain high-resolution 
three-dimensional images of body tissue. Signal 
contrast in MR images depends on the “relaxation” 
of in vivo water, which can be increased by adminis-
tering a contrast agent (CA). Many clinical contrast 
agents contain the paramagnetic Gadolinium(III) ion 
(Gd(III)).[1] Gd(III) cannot be administered as a free 
ion because of its high toxicity, so it is typically che-
lated with a compound such as diethylenetriamine-
pentaacetic acid (DTPA) or 1,4,7,10-tetraazacy-
clododecane-1,4,7,10-tetraacetic acid (DOTA) for 
use as an MRI agent. Despite the need for speci-
ficity, most CAs - including those based on DOTA 
and DTPA - circulate throughout the whole body and 
do not discriminate between various organs and tis-
sues. Effectively targeted MRI CAs would be very 
valuable, as lower doses would be sufficient and still 
provide sharper contrast in MR images compared 
to non-specific CAs. Some target-specific MRI CAs 
are already in clinical use; for instance, MS-325 
(Ablavar®) is used to image blood vessels.
A target-specific MRI CA can be prepared by 
linking a Gd(III) chelate to a receptor molecule that 
specifically recognizes the tissue of interest. While 
antibodies are commonly used as recognition mol-
ecules, aptamers are emerging as a more robust 
alternative. Aptamers are single-stranded DNA or 
RNA sequences that fold into distinct nanoscale 
shapes capable of binding specifically to a target 
molecule. Bernard and colleagues recently pub-
lished a proof-of-concept study, in which an aptamer 
was conjugated to a DTPA chelate. This conjugate 
was found to improve MRI contrast by about 30% in 
the presence of a target protein.[2]
Purpose
Thrombin is an enzyme that converts soluble fi-
brinogen into insoluble strands of fibrin, which works 
with platelets to form a blood clot. MR imaging of 
thrombin could be useful in visualizing blood clots
(thrombus and embolus). In this study, the objective 
was to develop a practical MRI contrast agent for 
imaging thrombin and blood clots by conjugating a 
specific aptamer to a chelate. A 29 base long DNA 
aptamer, isolated by Kubik et al, has been shown to 
bind to thrombin in blood clots and was used in this 
study of MRI contrast agents.
Materials and Methods
Synthesizing the Aptamer-Chelate Conjugate
The aptamers were synthesized by standard phos-
phoramidite chemistry on a MerMade 6 DNA syn-
thesizer. All amidites (bases) were prepared using 
specified volumes of acetonitrile for each base. The 
amidites and the synthesis columns were then loaded 
onto the MerMade synthesizer and the amino modifi-
er (NH2) was added. The file was then set up to spe-
cifically synthesize 5’-AGTCCGTGGTAGGGCAG-
GTTGGGGTGACT-3’.Two series of thrombin 
aptamer conjugates were prepared: one using the 
DTPA chelator, and the other using the DOTA che-
lator. These conjugates were prepared through the 
reaction between 5’-amino-modified aptamers and 
isothiocyanate-modified chelators to form a thiourea 
linkage (Figures 1 and 2). After the DNA synthesis 
was complete, the synthesis columns were washed 
in 10% diethylamine in anhydrous acetonitrile. The 
DNA was then washed with a deblocking reagent (2% 
dichloroacetic acid in dichloromethane). The beads 
were then transferred to a microcentrifuge tube and 
suspended in anhydrous dimethyl sulfoxide (DMSO) 
containing 15 μmol of either DTPA or DOTA chelates. 
The chelate reaction was allowed to react overnight. 
The beads were finally washed with DMSO and re-
acted for 24 hours with ammonium hydroxide before 
being dried on the speed vacuum.
Purifying the Aptamer-Chelate Conjugates
Following their synthesis, the conjugates were pu-
rified by polyacrylamide gel electrophoresis (PAGE). 
PAGE is a method of purifying and analysing DNA 
according to the size and charge of the molecule. 
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A 12% polyacrylamide gel was prepared by dis-
solving 31.5 g of urea in 23.5 mL acrylamide/bisacryl-
amide stock solution, 14 mL of water and 15 mL of 
5X TBE buffer. The solution was heated to 37°C, 
then filtered. 0.45 mL of 10% ammonium persulfate 
and 0.035 mL of TEMED were added to this remain-
ing solution; the solution was swirled quickly in the 
flask and poured into a gel-casting apparatus. The 
gels were allowed to polymerise for 30 minutes be-
fore samples were loaded and run. To prepare the 
samples, the DNA was dissolved in an equivolume of 
water and formamide, and the samples were heated 
to 55°C for 5 minutes. The dark band in the gel con-
taining the oligonucleotide was recovered. Finally, 
the gel/DNA solution was filtered, dried using a ly-
pholizer, and desalted.
Figure 1A. SCN - DOTA chelate
Figure 1B. SCN - DTPA chelate
Figure 2. Scheme for the preparation of aptamer-
MRI chelate conjugates; Thiourea conjugate reac-
tion: where R1 = the chelator and R2= the aptamer.
Analyzing the Aptamer-Chelate Conjugates
The modified chelators were quantified by UV Vis 
and sent for mass spectrometry. A separate sample 
was loaded with Gd(III) ions and subjected to the Xy-
lenol orange test for loading efficiency.
Results
Figure 3. PAGE purification; top: aptamer-DOTA 
conjugate, bottom: aptamer-DTPA conjugate.
Aptamer DNA was Successfully Synthesized
The thick, dark bands in Figure 3 suggest that the 
DNA was successfully synthesized. The bands con-
taining DNA were cut out and the DNA-chelate conju-
gates were extracted and desalted to purify the sam-
ple of extra salts and urea. Subsequently, the DNA 
was quantified by UV-Vis Spectroscopy.
Figure 4. UV-Vis absorbance spectrum of DNA for 
quantification of the DNA-chelate conjugates.
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The presence of DNA is indicated by a peak at ~260 
nm (Figure 4). Using the Beer-Lambert Law, we found 
that 296 nmol and 193 nmol of the aptamer-DOTA and 
aptamer-DTPA conjugates were respectively synthe-
sized. 3 nmol of each aptamer-chelate conjugate was 
sent for mass spectrometry to verify if the reaction was 
successful. 
Figure 5. Mass spectrometry results: DOTA first 
round of MS
Figure 6. Mass spectrometry results: DTPA first 
round of MS
Trace Amounts of the Aptamer-Chelate Conju-
gates were Synthesized
To determine whether the aptamer-chelate conju-
gate was successfully synthesized, the sample was 
assessed using mass spectrometry. After compar-
ing the masses observed in the spectra to the theo-
retical masses of the aptamer-DTPA and aptamer-
DOTA conjugates, it was evident that the conjugates 
had not been synthesized efficiently since the ma-
jor products (peaks at 9264.3 g/mol and 4064.2 g/
mol) were too small. The theoretical mass of the the 
aptamer-DOTA conjugate is 9952.9 g/mol and the 
theoretical mass of the aptamer-DTPA conjugate is 
9914.8 g/mol. Small traces of the conjugates may 
have been synthesized successfully; however, a 
side reaction with DMSO would have resulted in an 
unstable final product. The peak at ~10030 g/mol 
in both spectra is evidence that the side reaction 
occurred. 
Figure 7. Calibration curve from Xylenol Orange test.
Figure 8: Eppendorf tubes containing Xylenol Or-
ange test reactions.
Gd(III) Loading Efficiencies were Less Than 80%
After determining the molar quantities of the aptamer-
chelate conjugates, an equimolar amount of Gd(III) 
was reacted with them. The Xylenol Orange test 
was used to determine the concentration of Gd(III) 
that reacted with the conjugate (Figure 5). The ab-
sorbance ratios of the flow-through from the Gd(III) 
incubations were compared with absorbance ratios 
of known concentrations of Gd(III) (Figure 7 and 8). 
We found that the loading efficiencies of the chelates 
were less than 80%. For the loading efficiency to be 
higher, more Gd(III) should be added.
Discussion
Harnessing nanotechnology for use in the field of 
medicine is a burgeoning reality.  Here, its use as a 
diagnostic technique holds promise as some of these 
41
Figure 9. UV-Vis absorbance spectrum of Xylenol 
Orange test calibration curve.
techniques are in advanced stages of testing and are 
currently being used today.  MR imaging is a valued 
alternative to the conventional angiography and an-
gioscopy procedures to detect coronary thrombosis 
and the computed tomography pulmonary angiogram 
to detect pulmonary embolisms. This technology can 
be enhanced through the use of aptamer technology. 
A contrast agent developed using nanotechnology 
would specifically target the enzyme, thrombin, thus 
allow for precise imaging of blood clots. 
The amino-modified aptamer was successfully 
synthesized, purified and, subsequently, quantified 
in relatively high yield and purity compared to previ-
ous studies. Previous studies produced around 20 
nmol, whereas here, 96 nmol and 193 nmol were 
produced. 
The initial phase of this research generated re-
sults that require refining. When conjugating the ap-
tamer and the chelate, a side reaction with DMSO 
resulted in an unstable final product. The peak at 
~10030 g/mol in both spectra was evidence that 
the side reaction occurred. Future work will involve 
reacting the DNA once more with the DTPA/DOTA 
chelate to form the aptamer-chelate conjugate us-
ing, instead, an aqueous buffer (versus DMSO 
which is organic).  
We plan to screen two series of contrast agents, 
DOTA and DTPA, each conjugated to a thrombin-
specific aptamer, to find the best system for targeting 
thrombin in serum. This use of aptamer technology 
promises to be less invasive than traditional angiog-
raphy and angioscopy procedures. The first phase of 
this project, which is partially described in this paper, 
focuses on the synthesis of aptamer-DOTA and ap-
tamer-DTPA conjugates. Upon successful synthesis 
of the conjugates, they will be screened in the second 
phase of the project to find the best system for mea-
suring thrombin in serum. Physiological conditions 
will be created to test the robustness of our system 
in vivo. Once the second phase has been completed, 
we will modify the aptamer to dually locate the blood 
clot and burst it.
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review of Development Of An Aptamer-Based MRI Contrast 
Agent For Thrombin Detection
The author must truly be commended on the strength of her work and effort on this elegantly crafted manu-
script. It is inspiring to hear that this project was driven by secondary school student and her future is very 
bright in the medical sciences. Globally, the manuscript is articulate, robust and certainly well above the level 
of her training. Overall, this is an impressive manuscript and serves as a blueprint for her peers to aspire to.
The concept of harnessing nanotechnology for in essence ‘personalized’ or in this situation targeted medi-
cine is promising. There are some minor laboratory-clinical “disconnects” that I have outlined but with these very 
small revisions this should proceed to publication. 
Abstract
- Should use full form “magnetic resonance imaging (MRI)” before using short-form
- Is “blood clot” referring to arterial or venous thromboembolism – this should be clarified as it’s unclear.
- The link from targeted MRI contrast and system of measuring serum thrombin is unclear. This jump re-
quires clarification for the readership and is important.
 
Background
- Careful on clinical disconnect, MRI is not traditionally used clinically for detecting pulmonary embolism 
(PE) nor is invasive angiography conventional for diagnosing PE. CT-pulmonary embolism protocols standard 
and it is not invasive although does carry with it radiation.  VQ scans are also used for the diagnosis of PE and 
does not require conventional contrast.
- In terms of “affecting healthy cells” it’s unclear what the author is speculating on. Does she mean contrast 
induced nephropathy? This is usually CT contrast. MR traditionally uses gadolinium which is usually benign 
although can rarely lead to nephrogenic systemic fibrosis in dialysis patients. This is important to clarify if the 
author is suggesting targeted contrast may help avoid these possible, albeit rare side effects. This is alluded to 
in the background but should be clearer as it is the impetus for the current targeted contrast research.
- I caution the word “blood clotting” as it is colloquial and draw attention to the importance of clarifying 
venous or arterial venous thromboembolism – I presume VTE if you are referring to post-operative risks but 
would be well served to delineate.
- The sentence “Blood clotting during …” does not make clinical sense. VTE *prevention* isn’t really tech-
nology based (i.e DVT prophlaxis with low dose heparin, mobilization, etc). And if you mean VTE detection, 
although angiography/angioscopy is ‘classically’ the gold standard, it is rarely, if ever used for detection. CT 
angiography and Doppler ultrasound are most commonly used and carry with it minimal side effects. This part 
needs to be clarified and would suggest the acknowledgement of the above followed by stating the emergence 
of MRI in both arterial/venous thromboembolism detection given minimal radiation as compared to CT angio. 
However, current gadollinum contrast carries with it risks such as NSF, etc.
Materials and Methods
- Is the DNA synthesizer protocol validated? If so, need to include the protocol citation.
- Is PAGE protocol validated? If so, need to include the protocol citation
Results
- For “known value” would recommend you cite this.
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